https://www.selleckchem.com/pr....oducts/1-4-diaminobu
Sunitinib is a standard of care first line treatment for patients with metastatic renal cell carcinoma (RCC). Sunitinib standard dose is 50 mg once daily for 4 consecutive weeks followed by 2 weeks' off (4/2 schedule). Long-term and high exposure to this medication lead to severe adverse events (AEs); therefore, this trial was done to find the best schedule which gives the best outcome with minimal toxicity. Seventy patients were randomly assigned into 2 groups, then received 50 mg/day of sunitinib. Group 1 (40
Like
Comment
Share
